DLL3 and small cell lung carcinoma: Among these, SCLC-A and SCLC-N show higher DLL3 expression, thus being correlated with an enhanced susceptibility to DLL3-targeted therapies, whereas SCLC-P and SCLC-I show lower DLL3 expression, potentially limiting the therapeutic efficacy [81,82].